Tag: clinical development
-
Insmed to Present at the 44th Annual JP Morgan Healthcare Conference: What Investors Should Expect
Insmed to Present at the 44th Annual JP Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company, announced its plan to present at the 44th Annual JP Morgan Healthcare Conference. The conference, widely considered a bellwether event for the biopharma sector, will gather investors, analysts, and industry leaders to hear the latest…
-
Insmed to Present at the 44th Annual J.P. Morgan Healthcare Conference
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company, has announced that its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference. The conference, one of the most anticipated events in the biopharmaceutical industry, brings together investors, analysts, and industry leaders to discuss advances in science, clinical progress, and corporate strategy. Insmed’s participation…
-
Vasomune expands with AnGes partnership to broaden vascular damage therapy indications
Vasomune and AnGes announce expanded collaboration The Sunnybrook-based start-up Vasomune Therapeutics has strengthened its strategic alliance with Japanese biopharma company AnGes. The expanded partnership aims to broaden the indications for Vasomune’s lead drug candidate, which targets vascular damage and related cardiovascular conditions. The agreement comes with a $4 million funding commitment designed to accelerate development…
-
Vasomune Expands Partnership with AnGes to Advance Vascular Damage Drug Candidate
Overview: A Strategic Expansion in Vascular Therapy Sunnybrook-based startup Vasomune Therapeutics is broadening its collaboration with pharmaceutical giant AnGes to expand the indications for their leading drug candidate designed to treat vascular damage. The new agreement injects $4 million in funding to accelerate development, clinical milestones, and regulatory progress as the two companies pursue improved…
-
Improved Scientific Advice for Medicines Tackling Public Health Threats, Including Antimicrobial Resistance
Raising the Bar for Medicines and Vaccines against Public Health Threats Public health threats evolve rapidly, from novel pathogens to the growing challenge of antimicrobial resistance (AMR). In response, the European Medicines Agency’s Emergency Task Force (ETF) is refining its approach to provide higher-quality, earlier scientific advice for medicines and vaccines under development. The aim…
-
BlueWillow Biologics Demonstrates Promising Intranasal Bird Flu Vaccine in Nature Communications Study
BlueWillow’s Intranasal Bird Flu Vaccine: A Potential Game-Changer in Influenza Prevention BlueWillow Biologics, Inc., a clinical-stage biotech company at the forefront of intranasal vaccine technology, announced compelling results from a peer‑reviewed Nature Communications study. The research highlights the potential of the company’s intranasal bird flu vaccine to elicit robust mucosal and systemic immune responses, a…